Racionalʹnaâ Farmakoterapiâ v Kardiologii (2016-01-01)

REALITIES AND PROSPECTS FOR PHARMACOLOGICAL CORRECTION OF «ADMA-ENOS"-ASSOCIATED WAYS IN PREECLAMPSIA

  • M. V. Pokrovsky,
  • N. G. Filipenko,
  • M. V. Korokin,
  • V. V. Gureyev,
  • T. G. Pokrovsky,
  • A. A. Barsuk,
  • L. V. Korokina,
  • E. V. Proskuryakova,
  • N. V. Maltseva,
  • O. V. Levashova,
  • O. S. Gudyrev,
  • A. S. Belous,
  • O. S. Polyanskaya

DOI
https://doi.org/10.20996/1819-6446-2010-6-6-882-887
Journal volume & issue
Vol. 6, no. 6
pp. 882 – 887

Abstract

Read online

Methylated analogs of L-arginine - asymmetric dimetilarginin (ADMA) and monometilarginin (L-NMMA) - are endogenous inhibitors of endothelial NO-synthase (eNOS). ADMA level in maternal plasma is increased in women with preeclampsia. The high level of ADMA is one of the predictors of preeclampsia. L-arginine increases the activity of eNOS and production of nitric oxide in the ADMA-similar model of L-NAME-induced endothelial dysfunction. ENOS activator (resveratrol), antioxidants, potentiated polyclonal antibodies to eNOS and others agents have been effective in this model. Studies of endotelioprotective activity in other «ADMA-eNOS-associated" experimental models of metabolic syndrome and homocysteine-induced, gipoestrogen-induced sepsis-induced endothelial dysfunction and endothelial dysfunction in postvaccinal vasculitis have been developed.

Keywords